Answers are grounded in this paper and cite their sources.
Background/Methods: Levothyroxine (LT4) monotherapy fails to fully normalize thyroid hormone levels or relieve symptoms in 10–20% of hypothyroid patients, prompting interest in combination therapy with added liothyronine (LT3). Existing dosing guidance is largely qualitative. Using the p-THYROSIM mechanistic model—previously fitted and validated against data from 655 patients—we developed computational algorithms from ∼400 simulations to generate individualized residual thyroid function (RTF) values and combination LT4/LT3 dosing recommendations based on a patient’s sex, height ( H ), weight ( W ), and measured hormone values [TSH, free thyroxine (fT4), and free triiodothyronine (fT3) or total T3 (TT3)]. We implemented these in a user-friendly clinical software package as an app called LT43DOSING. Results: Simulated temporal plots of fT4, fT3, and TSH for combined dosages in available pill sizes are computed and reported as outputs of LT43DOSING, along with RTFs, separately for both sexes, with body mass indexes (BMIs) ranging from ∼15 to 40. Computed RTFs and dosages are based on patient H , W , and serum hormone concentrations provided as input data. Our findings show that both W and H affect dosing in a nonlinear manner, especially at BMI extremes, whereas sex made little difference. Only combination therapy was able to normalize fT3 levels. Conclusions: In simulated identical BMI patients, different H and W combinations produced markedly different RTF values, leading to more accurate dosing predictions based on body size. Simulated combination therapy normalized fT3 levels whereas monotherapy did not, particularly for overtly hypothyroid patients.
No takes yet. Share an insight, caveat, or question.
Reid et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: